Nevertheless, under the Companies Law, a company may not indemnify, exculpate or insure an Office Holder against any of the following:

Whole-cell currents were recorded from CHO-K1 cells transfected with HCN1, HCN2, or HCN4 channels 24–48 hours post-transfection. Glass pipettes were pulled to a final resistance of 2–4 MΩ. The external and internal solution were symmetrical and contained (in mM): 150 KCl, 10 HEPES pH 7.3, 2 MgCl2 and 1 EGTA. All recordings were performed after 2 mins of dialyzing the internal solution following membrane rupture in order to avoid issues of current rundown. Data were collected at 22–25 °C at 10 kHz with a 1 kHz low-pass Bessel filter using a conventional Axopatch 200B Amplifier and Digidata 1440A digitizer. Capacitance and series resistance were electronically compensated. Activation was assessed by stepping to voltages between −160 mV and −40 mV (Δ + 10 mV) from a holding potential (VH) of 0 mV, followed by a step to +30 mV. Steady-state activation curves were assessed from the peak of the tail currents. Non-equilibrium experiments involved a pre-pulse to −70 mV prior to the activation steps for a duration of 100 ms, 500 ms, or 1000 ms for HCN1, HCN2, and HCN4 respectively. Deactivation was assessed by a pre-pulse to −130 mV followed by test pulses from +50 mV to −60 mV (Δ-10 mV). Hysteresis was also assessed by ramps from 0 mV to −150 mV and back at varying speeds. For every protocol, each test pulse was followed by a 17–24 s interpulse interval at VH to ensure complete channel deactivation. Data were analyzed using pClamp 10 and Origin8.0 software packages.

Each U.S. Holder should consult its own tax adviser with respect to the applicability of the “net investment income tax” (discussed below) where a mark-to-market election is in effect.

In our Phase 2a placebo-controlled trial with 60 subjects with steatosis due to NAFLD or NASH, a similar proportion of patients from each treatment group reported adverse events (placebo 55%; Aramchol 100mg 40%, Aramchol 300mg 45%). Most adverse events were mild and transient. None of the adverse events reported in the Aramchol groups were considered related to the investigational drug. Three adverse events were initially considered to be related to the study drug; however, after un-blinding it turned out that they occurred in the placebo group. In addition, one serious adverse events (acute appendicitis) was reported in the placebo group. There were no deaths or other significant adverse events reported in this study.

Kaivosoja, E. et al. Chemical and physical properties of regenerative medicine materials controlling stem cell fate. Ann. Med. 44, 635–650 (2012).

        We cannot predict whether investors will find our common stock less attractive because we rely on certain of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

https://www.scientificamerican.com/article/aging-is-reversible-at-least-in-human-cells-and-live-mice/

Other than as described above, the Company did not have any material commitments for capital expenditures, including any anticipated material acquisition of plant and equipment or interests in other companies, as of December 31, 2018.

Circadian Technologies Limited (ASX:CIR.AX ) is a biologics drug developer focusing on cancer, cancer related and ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian’s internal product development programs are primarily focused on developing VGX-100 (a human antibody against VEGF-C) as a treatment for lymphedema resulting from breast cancer treatment and solid tumours, in particular glioblastoma and colorectal cancer, as well as developing VGX-300 (soluble VEGFR-3) for ‘back of the eye’ disease such as wet Age Related Macular Degeneration. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.

Palmer, R. M., Ferrige, A. G. & Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327, 524–526 (1987).

The obvious solutions are for the drug to be co-taken with sufficient crisped bacon, or co-formulated with ascorbic acid (something your body needs anyway).

The FDA’s standard is to be below an amount that would be expected (by their dose/response modeling) to cause 1 extra cancer case in 100,000 people who were taking the tablets at a standard dose for 70 straight years. That’s pretty stringent, considering the background rates of cancer in people who actually stay alive for 70 years in a row, especially when you factor in that no one goes on valsartan when they’re ten years old. Unfortunately, the ZHP material (according to the FDA) would be expected to cause one extra case of cancer with only 8,000 patients taking the highest dose of the drug for only four years, and that’s definitely unacceptable. It appears that the other manufacturers’ batches had contaminants at lower levels, from what I can see, although the amounts do not appear to have been specified.